Natural History Study of Adult Patients With Paroxysmal Nocturnal Hemoglobinuria of High-risk Hemolysis in China

NCT05125341 | Completed

• 1 other identifier: CAN106-01001
• Study Type: observational
• Target: 67
• Locations: 1 country
• Sites: 1

Brief Summary

This is a single-center observational study conducted in adult patients with paroxysmal nocturnal hemoglobinuria of high-risk hemolysis. This observational study consists of two parts, one part is retrospective study which aims to collect medical chart data to calculate the mean change or mean incidence rates of LDH, hemoglobin, PNH-related symptoms and PNH-related events over 6 months. The other part is cross-sectional study to detect the total C5 level in PUMCH at the latest follow-up visit in eligible PNH patients with high-risk hemolysis, to show the difference between eligible PNH patients and healthy people and to explore the related clinical factor influencing high-level total C5 using logistic regression model.

Conditions

Paroxysmal Nocturnal Hemoglobinuria, Natural History Study

Outcome Measures

Primary Outcomes (1)

• the mean change of LDH

  the mean change of LDH over 6 months

  6 months

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Adult patients with paroxysmal nocturnal hemoglobinuria of high-risk hemolysis in China

You may qualify if:

• Meet the diagnostic criteria for paroxysmal nocturnal hemoglobinuria;
• Age ≥ 18 years old;
• PNH clone size of granulocytes or monocytes (CD59 or Flaer) ≥ 10%;
• LDH≥1.5 ULN;
• Accompanied by at least one PNH-related symptoms: fatigue, hemoglobinuria, abdominal pain, dyspnea, anemia symptoms, major adverse vascular events (including thrombosis), dysphagia, erectile dysfunction;
• Transfusion-dependent PNH patients;
• There are at least 6 months consecutive data of diagnosis and treatment after the data collection time point;
• Patients agreed to participate in the study by signing informed consent or giving oral informed consent.

You may not qualify if:

• Patients are under the treatment of the C1/C3/C5 complement inhibitors currently or in the past;
• Patients have received bone marrow transplantation;
• platelet count \<30\*10 9/L or absolute neutrophil count \<0.5\*10 9/L;
• Patients have clinically significant heart, liver, or lung diseases, or have related medical history.
• Patients have comorbidities of rheumatoid disease, HIV infection, active HBV infection, HCV infection and other diseases that affect the body's immune function;
• Severe missing data in the records of diagnosis and treatment after the data collection time point;
• Other patients who are not suitable to participate in the study.

Sponsors & Collaborators

• CARE Pharma Shanghai Ltd.: lead

Study Sites (1)

Peking Union Medical College Hospital

Beijing, China

Location

MeSH Terms

Conditions

Hemoglobinuria, Paroxysmal

Condition Hierarchy (Ancestors)

Anemia, Hemolytic; Anemia; Hematologic Diseases; Hemic and Lymphatic Diseases; Myelodysplastic Syndromes; Bone Marrow Diseases

Study Officials

• Bing Han, MD

  Peking Union Medical College Hospital

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: OTHER
• Time Perspective: OTHER
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: November 8, 2021
• First Posted: November 18, 2021
• Study Start: November 25, 2021
• Primary Completion: March 16, 2022
• Study Completion: April 30, 2022
• Last Updated: July 5, 2022

Record last verified: 2021-11

Locations

CN (1)